SOPHiA GENETICS (NASDAQ:SOPH) Stock: Insider Well Daan Van Sells 6,168 Shares

SOPHiA GENETICS SA (NASDAQ:SOPH) insider Well Van sold 6,168 shares of the firm’s stock in a transaction on Monday, October 5th. The shares were sold at an average price of $8.12, for a total transaction of $50,084.16. Following the completion of the sale, the insider owned 332,716 shares in the company, valued at $2,701,653.92. The trade was a 1.82% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Well Daan Van also recently made the following trade(s):

• On Friday, September 11th, Well Van sold 6,168 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $7.63, for a total transaction of $47,061.84.

SOPHiA GENETICS Stock Performance

NASDAQ:SOPH opened at $7.30 on Friday. The firm has a market capitalization of $612.40 million, a PE ratio of -6.35 and a beta of 0.95. The business’s fifty day moving average price is $7.88 and its 200 day moving average price is $6.15. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.69 and a quick ratio of 2.55. SOPHiA GENETICS SA has a 12 month low of $3.75 and a 12 month high of $8.98.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). The business had revenue of $23.31 million for the quarter, compared to analysts’ expectations of $21.72 million. SOPHiA GENETICS had a negative return on equity of 132.47% and a negative net margin of 93.86%. On average, sell-side analysts anticipate that SOPHiA GENETICS SA will post -0.77 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

SOPH has been the subject of a number of research analyst reports. Zacks Research raised SOPHiA GENETICS to a “hold” rating in a report on Tuesday, July 21st. Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Friday, July 17th. HC Wainwright upped their target price on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. Finally, BTIG Research upped their target price on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, SOPHiA GENETICS has an average rating of “Hold” and a consensus price target of $10.00.

Trending Headlines about SOPHiA GENETICS

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: Myriad Genetics and SOPHiA GENETICS are partnering with AstraZeneca to use prostate cancer technology involving genomic-instability scoring. The agreement provides potential commercial and validation benefits for SOPH by connecting its analytics capabilities with Myriad’s testing expertise and AstraZeneca’s oncology development programs. Myriad, SOPHiA partner with AstraZeneca to use prostate cancer technology
• Positive Sentiment: The collaboration reinforces SOPHiA GENETICS’ positioning in cancer genomics and could increase adoption of its cloud-based SOPHiA DDM platform. However, the reports do not disclose financial terms, revenue guidance or a specific near-term contribution, so the immediate earnings impact remains uncertain. SOPHiA GENETICS Partners Myriad Genetics To Advance Prostate Genomic Instability Score Technology
• Neutral Sentiment: Several executives and directors, including the CEO, chairman, CFO and CTO, sold shares at approximately $8.04–$8.13. The sales were made under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested equity awards, and each insider retained a substantial position. SOPHiA GENETICS insider trading report
• Negative Sentiment: The broad group of insider sales totaled roughly $669,000 and may create some near-term selling pressure or investor caution, despite the transactions appearing administrative rather than discretionary bearish bets.

Institutional Trading of SOPHiA GENETICS

Several institutional investors and hedge funds have recently made changes to their positions in the company. AWM Investment Company Inc. acquired a new position in SOPHiA GENETICS during the second quarter worth approximately $9,809,000. Principal Financial Group Inc. boosted its holdings in shares of SOPHiA GENETICS by 0.7% in the first quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company’s stock valued at $6,976,000 after acquiring an additional 9,800 shares during the period. Hodges Capital Management Inc. purchased a new position in shares of SOPHiA GENETICS during the first quarter worth approximately $2,157,000. Sei Investments Co. acquired a new position in shares of SOPHiA GENETICS in the 1st quarter valued at $1,772,000. Finally, 1492 Capital Management LLC raised its position in SOPHiA GENETICS by 8.4% in the 1st quarter. 1492 Capital Management LLC now owns 225,751 shares of the company’s stock valued at $1,117,000 after purchasing an additional 17,406 shares during the last quarter. 31.59% of the stock is owned by hedge funds and other institutional investors.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS is a healthcare technology company that develops cloud-based data analytics solutions for the life sciences and healthcare industries. Its platform is designed to help organizations analyze and interpret complex genomic and multimodal data to support more informed clinical and research decisions.

The company’s principal offering, the SOPHiA DDM platform, combines data management, analytics and artificial intelligence capabilities. It supports applications including cancer genomics, hereditary disease analysis, reproductive health and other areas of precision medicine.